Quick Answer

CagriSema is an investigational combination drug that pairs cagrilintide (amylin analog) with semaglutide (GLP-1) for enhanced weight loss. Early trials show it may produce greater weight loss than semaglutide alone, but it's not yet FDA-approved or available by prescription. Current GLP-1 medications remain the best option while CagriSema completes clinical trials.

Key Points

• CagriSema combines cagrilintide (appetite suppressant) with semaglutide (GLP-1 receptor agonist) for dual-action weight loss
• Early clinical trials show greater weight loss than semaglutide (Wegovy/Ozempic) alone
• Still in development with FDA approval expected in coming years, not yet available by prescription
• Side effect profile appears similar to current GLP-1 medications (nausea, GI effects)
• Represents next generation of combination GLP-1 therapies for obesity treatment
• Current GLP-1 medications remain the approved and available treatment option

Statistics

• CagriSema combines two drugs: cagrilintide (amylin analog) + semaglutide (GLP-1 RA) (Novo Nordisk, 2025)
• Early trials show enhanced weight loss vs. semaglutide 2.4mg alone (STEP trials comparison)
• FDA approval timeline: Expected 2027-2028 (Novo Nordisk development pipeline)
• Dual-mechanism approach targets multiple pathways for appetite and food intake regulation

Medical Review

This article was reviewed by the GLP Spot Medical Review Board. Our medical review process ensures all content reflects current clinical trial data and FDA guidance on investigational GLP-1 medications.

CagriSema: The Next-Gen GLP-1 Drug

CagriSema is a new drug that combines two medications into one. Early studies suggest it could be stronger than Wegovy and Zepbound.

What Is CagriSema?

It's a two-in-one drug that combines:

• Cagrilintide – An amylin analog that controls appetite
• Semaglutide – The same ingredient in Ozempic and Wegovy

Together, they target multiple pathways for more weight loss than either drug alone.

What Research Shows

Early studies suggest CagriSema may beat current options:

• Higher weight loss than semaglutide alone
• Better blood sugar control
• Potentially better results for people with obesity or type 2 diabetes

How It Works

1. Semaglutide reduces appetite and slows digestion
2. Cagrilintide helps control appetite and reduces food intake

Two mechanisms. One shot. More effect.

What We Know So Far

Trial Results

• Significant weight loss in clinical trials
• Both drugs work together through different pathways
• Side effects look similar to other GLP-1 meds

Timeline

• Still in development
• Not yet available by prescription
• FDA approval expected in the coming years

What This Means for You

CagriSema represents the next wave of GLP-1 meds — combination drugs that may work better than single-drug options.

But it's not available yet. Current GLP-1 meds remain your best option right now.

Questions for Your Doctor

1. When might CagriSema become available?
2. Will it be right for me?
3. How does it compare to what's available now?
4. What should I do in the meantime?

The Bottom Line

CagriSema looks promising but isn't available yet. Current GLP-1 medications remain the approved treatment options. Talk to your doctor about what's best for you now.

This article is for information only. Work with your healthcare provider to find the best treatment. This is not medical advice.